Asset
OBEFAZIMOD
Abivax SA American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (18)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02990325 | phase1_2 | completed | 2017-03-27 | 2018-12-27 | Abivax S.A. | A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults |
| NCT05535946 | phase3 | active_not_recruiting | 2023-01-16 | 2026-04-28 | Abivax S.A. | ABTECT - Maintenance |
| NCT05507203 | phase3 | completed | 2022-10-10 | 2025-06-24 | Abivax S.A. | ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 |
| NCT05507216 | phase3 | completed | 2022-12-21 | 2025-06-24 | Abivax S.A. | ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 |
| NCT02792686 | phase1 | completed | 2014-03-01 | 2014-07-01 | Abivax S.A. | ABX464 First in Man Study |
FDA applications (0)
This company has no applications containing this asset.